EQS-Adhoc: H&R GmbH & Co. KGaA: Preliminary Figures for nine month period of 2025

Insider information pursuant to Article 17

of the Market Abuse Regulation [MAR] 

H&R GmbH & Co. KGaA: Preliminary Figures for nine month period of 2025

• Business slows down in terms of sales revenue and earnings
• EBITDA at EUR 60.5 million, around 8 percent below the previous year's level (nine months of 2024: EUR 65.9 million)

Salzbergen, Germany, October 22, 2025. H&R GmbH & Co. KGaA (H&R KGaA for short; ISIN DE000A2E4T77) reported a slowdown in sales revenue and earnings at the end of the third quarter of 2025. According to preliminary calculations, consolidated operating earnings (EBITDA - consolidated earnings before income taxes, other financial income and expenses, depreciation and amortization, and impairment losses and write-ups on intangible assets and property, plant, and equipment) amounted to EUR 20.3 million in the third quarter, down on the same quarter of the previous year (Q3 2024: EUR 24.8 million). At the same time, earnings for the first three quarters of the current fiscal year are showing a wave-like pattern (EBITDA Q1-2025: EUR 22.4 million; Q2-2025: EUR 17.7 million). The other results in detail: EBIT closed at EUR 5.5 million, compared with EUR 9.0 million last year. Earnings before taxes (EBT) amounted to EUR 2.6 million in the third quarter of 2025 (Q3-2024: EUR 5.8 million), while the company posted a consolidated net income attributable to shareholders of EUR -0.7 million (Q3-2024: EUR 3.5 million). Sales revenues in the third quarter of the current fiscal year decreased by 8.1 percent to EUR 310.6 million (Q3-2024: EUR 338.1 million).

Looking at the nine-month period as a whole in 2025, the Group achieved a reduced preliminary EBITDA of EUR 60.5 million (nine months of 2024: EUR 65.9 million) and weaker sales revenue of EUR 963.7 million (nine months of 2024: EUR 1,013.6 million). The other earnings levels also developed modestly: EBIT for the nine-month period was EUR 16.4 million (nine months of 2024: EUR 20.6 million). A comparable trend was also seen in earnings before taxes (EBT), which amounted to EUR 7.5 million (nine months 2024: EUR 11.1 million). Consolidated net income attributable to shareholders closed at EUR -0.4 million (nine months 2024: EUR 6.3 million). H&R KGaA thus generated a loss per share of EUR -0.01. With a result of EUR -0.02, the third quarter of 2025 (nine months of 2024: EUR 0.17; Q3 2024: EUR 0.09) caused the result to turn negative.

In addition to lower input material costs, the overall economic situation had an impact on H&R's business volume. Lower demand was noticeable across all segments.

The ChemPharm REFINING segment once again made the largest contribution to earnings. Unlike the two previous quarters of 2025, however, the third quarter of 2025 performed weaker than the same quarter of the previous year, with EBITDA of EUR 13.7 million (Q3 2024: EUR 15.3 million). However, the outlook for the first nine months as a whole was more encouraging: at EUR 40.7 million (nine months of 2024: EUR 35.8 million), the segment's performance improved. Sales revenue in the segment reached EUR 597.0 million for the nine-month period (nine months of 2024: EUR 621.8 million).

Our international activities in the ChemPharm SALES segment recorded lower operating results of EUR 9.0 million in the third quarter and EUR 26.8 million in the nine-month period (Q3 2024: EUR 9.7 million; nine months 2024: EUR 30.8 million). Sales revenue in the nine-month period remained below the previous year at EUR 351.6 million and EUR 114.5 million in the quarter (nine months 2024: EUR 370.2 million; Q3 2024: EUR 126.6 million).

Once again, the PLASTICS segment recorded the heaviest losses. It generated a significantly higher loss of EUR -3.7 million for the nine-month period (nine months of 2024: EUR 1.7 million), almost half of which was caused by the third quarter of 2025 (Q3 2025: EUR -1.8 million; Q3 2024: EUR 0.5 million). Sales Revenue also declined compared with the previous year's figures, at EUR 27.6 million and EUR 8.8 million (nine months of 2024: EUR 36.3 million; Q3 2024: EUR 12.1 million), primarily as a result of the continuing tense situation in the automotive industry. 

Operating cash flow for the nine-month period in 2025 was weaker than in the same period of the previous year, at EUR 44.4 million (nine months of 2024: EUR 53.8 million). Although a lower consolidated result had already been anticipated, it was alleviated during the year primarily by lower input material costs and the resulting reduction in net working capital. In the third quarter of 2025, however, it amounted to a significantly reduced EUR 19.8 million (Q3 2024: EUR 48.3 million), and free cash flow amounted to EUR 3.8 million (Q3 2024: EUR 36.2 million). At the end of the nine-month period, free cash flow stood at EUR 8.8 million, compared with EUR 17.6 million in the previous year.

Total assets decreased from EUR 1,014.8 million as of December 31, 2024, to EUR 983.6 million. Equity declined from EUR 468.6 million to EUR 452.1 million over the same period. As of September 30, 2025, the company's equity ratio was 46.0% (December 31, 2024: 46.2%).

Since the summer, the company's business and earnings performance has recovered slightly, but has nevertheless failed to meet the more optimistic expectations overall. Overall, H&R is thus on track to achieve the lower range of its EBITDA forecast, which was recently reduced to EUR 77.0 million. Further details will be provided as necessary in the course of the year.

The final financial figures and further information on business development in 2025 to date will be published as planned in the quarterly report on November 14, 2025.

Contact information:

H&R GmbH & Co. KGaA, Head of Investor Relations/Communications, Ties Kaiser

Neuenkirchener Strasse 8, 48499 Salzbergen

Tel.: +49 40 43218-321, Fax: +49 40 43218-390

e-mail: ties.kaiser@hur.com ; www.hur.com

H&R GmbH & Co. KGaA:

H&R GmbH & Co. KGaA, listed in the Prime Standard segment of the Frankfurt Stock Exchange, is a specialty chemicals company engaged in the development and manufacture of specialty chemical and pharmaceutical products based on fossil, bio-based, synthesized, and recycled hydrocarbons, and in the production of precision plastic parts.

Forward-looking statements and forecasts:

This press release contains forward-looking statements. The statements are based on the current estimates and forecasts by the Executive Board and the information available to the Board at this time. These forward-looking statements do not provide any warranty for the future developments and results contained therein. The future developments and results are dependent on a number of factors; they entail various risks and contingencies and are based on assumptions which could prove to be incorrect. We do not assume any responsibility for updating the forward-looking statements contained in this press release.